SCHEMBL19924468

SCHEMBL19924468

O=c1ccc2ccccc2n1-c1c[nH]c2ccccc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.41
BRD4 O60885 1/20 0.41
BRPF1 P55201 1/20 0.41
CA9 Q16790 1/20 0.41
KAT2B Q92831 1/20 0.41
BRD9 Q9H8M2 1/20 0.41
SIRT2 Q8IXJ6 2/20 0.38
SIRT1 Q96EB6 1/20 0.38
CCNE2 O96020 2/20 0.37
CDK4 P11802 2/20 0.37
PRKACA P17612 2/20 0.37
PRKACG P22612 2/20 0.37
PRKACB P22694 2/20 0.37
CCND1 P24385 2/20 0.37
CCNE1 P24864 2/20 0.37
CDK2 P24941 2/20 0.37
PIM1 P11309 2/20 0.37
PRKD3 O94806 1/20 0.37
CCNB2 O95067 1/20 0.37
ABL1 P00519 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17861173 0.77 ATM (0.45) SIRT2SIRT1GPR84CYP2A6IMPDH2
SCHEMBL8520286 0.76 HSP90AA1 (0.54) SIRT2SIRT1MEN1MAPTKMT2A
SCHEMBL7372110 0.73 PRKD3 (0.44) CDK4PRKACAPRKACGPRKACBCCND1
SCHEMBL29009659 0.72 CA12 (0.47) CA12BRD4BRPF1CA9KAT2B
SCHEMBL27993072 0.72 PRKD3 (0.42) CDK4PRKACAPRKACGPRKACBCCND1
SCHEMBL4020602 0.71 NR4A2 (0.50) SIRT2PRKCAGPR84MEN1MAPT
SCHEMBL17505155 0.69 CA12 (0.47) CA12BRD4BRPF1CA9KAT2B
SCHEMBL9270290 0.69 POLB (0.50) CA12BRD4BRPF1CA9KAT2B
SCHEMBL19444481 0.69 SIRT2 (0.40) SIRT2SIRT1CCNE2CDK4PRKACA
SCHEMBL500223 0.69 CA12 (0.43) CA12BRD4BRPF1CA9KAT2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018042096-A1 2-QUINOLIN-2-ONE DERIVATIVES AS MODULATORS OF NMDA RECEPTORS, COMPOSITIONS COMPRISING SAME AND USE OF THESE COMPOUNDS IN THE TREATMENT OF DISEASES INVOLVING THE CENTRAL NERVOUS SYSTEM ADPUERIVITAM (FR) 2018-03-08 WO disclosed